New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

Marika Cinausero, Giuseppe Aprile, Paola Ermacora, Debora Basile, Maria G Vitale, Valentina Fanotto, Giuseppe Parisi, Lorenzo Calvetti, Stephen T Sonis, Marika Cinausero, Giuseppe Aprile, Paola Ermacora, Debora Basile, Maria G Vitale, Valentina Fanotto, Giuseppe Parisi, Lorenzo Calvetti, Stephen T Sonis

Abstract

Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is topical and several estimations of additional hospital costs due to this clinical condition have been recently reported. The ability to determine risk factors for mucositis, to early detect its onset, to assess correctly the degree of this toxicity and to plan its multidisciplinary management are all key elements to guarantee the quality of life of patients and to avoid useless dose reduction or interruption of treatment. The pathogenesis of mucositis is multifactorial and it is classily subdivided into oral and gastrointestinal mucositis according to its anatomic presentation. Treatment and patients' related factors might help in predicting the frequency and the potential degree of symptoms onset. Here we discuss about clinical presentation and pathogenesis of mucositis in relation to different kinds of treatments. Moreover, we focus on therapeutic and prevention strategies, describing past and present management according to international guidelines and the most promising new data about agents potentially able to further improve the treatment of mucositis in the next future.

Keywords: anticancer treatment; gastrointestinal mucositis; management; oral mucositis; pathobiology.

Figures

FIGURE 1
FIGURE 1
Pathobiology of mucositis. With permission of Sonis (2007). “Reprinted with permission from Frontline Medical Communications, Inc.”

References

    1. Abayomi J., Kirwan J., Hackett A. (2009). The prevalence of chronic radiation enteritis following radiotherapy for cervical or endometrial cancer and its impact on quality of life. Eur. J. Oncol. Nurs. 13 262–267. 10.1016/j.ejon.2009.02.007
    1. Abdel-Rahman O., ElHalawani H., Essam-Eldin S. (2016). S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. Expert Opin. Drug Saf. 15 5–20. 10.1517/14740338.2016.1105959
    1. Abdel-Rahman O., Fouad M. (2015). Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Expert Rev. Anticancer Ther. 15 847–858. 10.1586/14737140.2015.1047350
    1. Adebahr S., Schimek-Jasch T., Nestle U., Brunner T. B. (2016). Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies. Best Pract. Res. Clin. Gastroenterol. 30 565–580. 10.1016/j.bpg.2016.07.003
    1. Ala S., Saeedi M., Janbabai G., Ganji R., Azhdari E., Shiva A. (2016). Efficacy of sucralfate mouth wash in prevention of 5-fluorouracil induced oral mucositis: a prospective, randomized, double-blind, controlled trial. Nutr. Cancer 68 456–463. 10.1080/01635581.2016.1153666
    1. Al-Ansari S., Zecha J. A. E. M., Barasch A., de Lange J., Rozema F. R., Raber-Durlacher J. E. (2015). Oral mucositis induced by anticancer therapies. Curr. Oral Health Rep. 2 202–211. 10.1007/s40496-015-0069-4
    1. Al-Dasooqi N., Gibson R. J., Bowen J. M., Logan R. M., Stringer A. M., Keefe D. M. (2010). Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp. Biol. Med. 235 1244–1256. 10.1258/ebm.2010.010082
    1. Al-Dasooqi N., Sonis S. T., Bowen J. M., Bateman E., Blijlevens N., Gibson R. J., et al. (2013). Emerging evidence on the pathobiology of mucositis. Support. Care Cancer 21 2075–2083. 10.1007/s00520-013-1810-y
    1. Allison R. R., Ambrad A. A., Arshoun Y., Carmel R. J., Ciuba D. F., Feldman E., et al. (2014). Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer 120 1433–1440. 10.1002/cncr.28553
    1. Aprile G., Rihawi K., De Carlo E., Sonis S. T. (2015). Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: a critical update. World J. Gastroenterol. 21 11793–11803. 10.3748/wjg.v21.i41.11793
    1. Arbabi-kalati F., Arbabi-kalati F., Deghatipour M., Ansari Moghadam A. (2012). Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: a double-blind randomized clinical trial. Arch. Iran. Med. 15 413–417.
    1. Azizi A., Alirezaei S., Pedram P., Mafi A. R. (2015). Efficacy of topical and systemic vitamin e in preventing chemotherapy-induced oral mucositis. Rep. Radiother. Oncol. 2:e796 10.5812/rro.2(1)2015.796
    1. Barasch A., Peterson D. E., Tanzer J. M., D’Ambrosio J. A., Nuki K., Schubert M. M., et al. (1995). Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 76 2550–2556. 10.1002/1097-0142(19951215)76:12<2550::AID-CNCR2820761222>;2-X
    1. Baydar M., Dikilitas M., Sevinc A., Aydogdu I. (2005). Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J. Natl. Med. Assoc. 97 1161–1164.
    1. Blijlevens N., Sonis S. (2007). Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann. Oncol. 18 817–826. 10.1093/annonc/mdl332
    1. Boers-Doets C. B., Epstein J. B., Raber-Durlacher J. E., Ouwerkerk J., Logan R. M., Brakenhoff J. A., et al. (2012). Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17 135–144. 10.1634/theoncologist.2011-0111
    1. Boers-Doets C. B., Lalla R. V. (2013). The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis. Supp. Care Cancer 21(Suppl. 1) S140.
    1. Bonner J. A., Giralt J., Harari P. M., Baselga J., Spencer S., Bell D., et al. (2016). Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: assessment from a phase 3 registration trial. Eur. J. Cancer 64 1–11. 10.1016/j.ejca.2016.05.008
    1. Bossi P., Bergamini C., Miceli R., Cova A., Orlandi E., Resteghini C., et al. (2016). Salivary cytokine levels and oral mucositis in head and neck cancer patients treated with chemotherapy and radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 96 959–966. 10.1016/j.ijrobp.2016.08.047
    1. Bossi P., Lucchesi M., Antonuzzo A. (2015). Gastrointestinal toxicities from targeted therapies: measurement, duration and impact. Curr. Opin. Support. Palliat. Care 9 163–167. 10.1097/SPC.0000000000000128
    1. Bowen J. M., Gibson R. J., Keefe D. M., Cummins A. G. (2005). Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37 56–62. 10.1080/00313020400023461
    1. Bowen J. M., Gibson R. J., Keefe D. M. K. (2011). Animal models of mucositis: implications for therapy. J. Support. Oncol. 9 161–168. 10.1016/j.suponc.2011.04.009
    1. Campos M. I. D. C., Campos C. N., Aarestrup F. M., Aarestrup B. J. V. (2014). Oral mucositis in cancer treatment: natural history, prevention and treatment. Mol. Clin. Oncol. 2 337–340. 10.3892/mco.2014.253
    1. Cascinu S., Fedeli A., Fedeli S. L., Catalano G. (1994). Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur. J. Cancer. B. Oral Oncol. 30B 234–236. 10.1016/0964-1955(94)90003-5
    1. Chansky K., Benedetti J., Macdonald J. S. (2005). Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103 1165–1171. 10.1002/cncr.20878
    1. Chaveli-López B. (2014). Oral toxicity produced by chemotherapy: a systematic review. J. Clin. Exp. Dent. 6 e81–e90. 10.4317/jced.51337
    1. Chaveli-López B., Bagán-Sebastián J. V. (2016). Treatment of oral mucositis due to chemotherapy. J. Clin. Exp. Dent. 8 e201–e209. 10.4317/jced.52917
    1. Chen P., Mancini M., Sonis S. T., Fernandez-Martinez J., Liu J., Cohen E. E. W., et al. (2016). A novel peptide for simultaneously enhanced treatment of head and neck cancer and mitigation of oral mucositis. PLoS ONE 11:e0152995 10.1371/journal.pone.0152995
    1. Chen Y.-K., Hou H.-A., Chow J.-M., Chen Y.-C., Hsueh P.-R., Tien H.-F. (2011). The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 30 753–759. 10.1007/s10096-010-1148-z
    1. Cho H.-J., Park Y. S., Kang W. K., Kim J.-W., Lee S.-Y. (2007). Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther. Drug Monit. 29 190–196. 10.1097/FTD.0b013e318040b1fe
    1. Ciorba M. A. (2012). A gastroenterologist’s guide to probiotics. Clin. Gastroenterol. Hepatol. 10 960–968. 10.1016/j.cgh.2012.03.024
    1. Ciorba M. A., Hallemeier C. L., Stenson W. F., Parikh P. J. (2015). Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr. Opin. Support. Palliat. Care 9 157–162. 10.1097/SPC.0000000000000134
    1. ClinicalTrials. gov (2016a). A Mouth Rinse Containing East Indian Sandalwood Oil (EISO) for the Prevention and Treatment of Oral Mucositis Available at: [accessed December 9, 2016].
    1. ClinicalTrials. gov (2016b). Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant. Available at: [accessed December 13, 2016].
    1. ClinicalTrials. gov (2016c). Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer. Available at: [accessed December 9, 2016].
    1. ClinicalTrials. gov (2016d). Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers. Available at: [accessed December 9, 2016].
    1. ClinicalTrials. gov (2016e). Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy. Available at: [accessed December 9, 2016].
    1. ClinicalTrials. gov (2016f). Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects. Available at: [accessed December 7, 2016].
    1. ClinicalTrials. gov (2016g). The Impact of Pentoxifylline and Vitamin E on Radiotherapy-Induced Toxicity in Head & Neck Cancer Patients. Available at: [accessed December 9, 2016].
    1. ClinicalTrials. gov (2017a). A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer. Available at: [accessed January 30, 2017].
    1. ClinicalTrials. gov (2017b). Phase 2 Study to Evaluate the Safety & Efficacy of Brilacidin Oral Rinse in Patients With Head and Neck Cancer. Available at: [accessed January 30, 2017].
    1. Cowen D., Tardieu C., Schubert M., Peterson D., Resbeut M., Faucher C., et al. (1997). Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 38 697–703. 10.1016/S0360-3016(97)00076-X
    1. Davila M. L. (2006). Neutropenic enterocolitis. Curr. Opin. Gastroenterol. 22 44–47.
    1. De Sanctis V., Bossi P., Sanguineti G., Trippa F., Ferrari D., Bacigalupo A., et al. (2016). Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Crit. Rev. Oncol. Hematol. 100 147–166. 10.1016/j.critrevonc.2016.01.010
    1. Dodd M. J., Dibble S. L., Miaskowski C., MacPhail L., Greenspan D., Paul S. M., et al. (2000). Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 90 39–47. 10.1067/moe.2000.105713
    1. Douillard J. Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., et al. (2014). Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 25 1346–1355. 10.1093/annonc/mdu141
    1. El-Housseiny A. A., Saleh S. M., El-Masry A. A., Allam A. A. (2007). The effectiveness of vitamin “E” in the treatment of oral mucositis in children receiving chemotherapy. J. Clin. Pediatr. Dent. 31 167–170. 10.17796/jcpd.31.3.r8371x45m42l10j7
    1. Elting L. S., Chang Y.-C., Parelkar P., Boers-Doets C. B., Michelet M., Hita G., et al. (2013). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer 21 3243–3254. 10.1007/s00520-013-1821-8
    1. Elting L. S., Cooksley C., Chambers M., Cantor S. B., Manzullo E., Rubenstein E. B. (2003). The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 1531–1539. 10.1002/cncr.11671
    1. Epstein J. B., Silverman S., Paggiarino D. A., Crockett S., Schubert M. M., Senzer N. N., et al. (2001). Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92 875–885. 10.1002/1097-0142(20010815)92:4<875::AID-CNCR1396>;2-1
    1. Farrell C. L., Bready J. V., Rex K. L., Chen J. N., DiPalma C. R., Whitcomb K. L., et al. (1998). Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 58 933–939.
    1. Ferreira B., da Motta Silveira F. M., de Orange F. A. (2016). Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial. Support. Care Cancer 24 1035–1042. 10.1007/s00520-015-2881-8
    1. Ghoreishi Z., Shidfar F., Iravani M., Esfahani A., Ghavamzadeh A. (2007). Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation. Asia Pac. J. Clin. Oncol. 3 113–118. 10.1111/j.1743-7563.2007.00111.x
    1. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., et al. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Lond. Engl. 381 303–312. 10.1016/S0140-6736(12)61900-X
    1. Han X., Wu Z., Di J., Pan Y., Zhang H., Du Y., et al. (2011). CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. Biomed. Pharmacother. Biomedecine Pharmacother. 65 547–554. 10.1016/j.biopha.2011.03.008
    1. Hartmann J. T., Lipp H.-P. (2003). Toxicity of platinum compounds. Expert Opin. Pharmacother. 4 889–901. 10.1517/14656566.4.6.889
    1. Heinemann V., Weikersthal L. F., von Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S.-E., et al. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15 1065–1075. 10.1016/S1470-2045(14)70330-4
    1. Hernández-Moreno A., Vidal-Casariego A., Calleja-Fernández A., Kyriakos G., Villar-Taibo R., Urioste-Fondo A., et al. (2015). Chronic enteritis in patients undergoing pelvic radiotherapy: prevalence, risk factors and associated complications. Nutr. Hosp. 32 2178–2183. 10.3305/nh.2015.32.5.9562
    1. Kazemian A., Kamian S., Aghili M., Hashemi F. A., Haddad P. (2009). Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur. J. Cancer Care 18 174–178. 10.1111/j.1365-2354.2008.00943.x
    1. Keefe D. M., Elting L. S., Nguyen H. T., Grunberg S. M., Aprile G., Bonaventura A., et al. (2014). Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. Cancer Chemother. Pharmacol. 74 675–680. 10.1007/s00280-014-2526-5
    1. Koukourakis M. I., Maltezos E. (2006). Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. Anticancer. Drugs 17 133–138. 10.1097/00001813-200602000-00003
    1. Krishna S. G., Zhao W., Grazziutti M. L., Sanathkumar N., Barlogie B., Anaissie E. J. (2011). Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 117 648–655. 10.1002/cncr.25633
    1. Kudrimoti M., Curtis A., Azawi S., Worden F., Katz S., Adkins D., et al. (2016). Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J. Biotechnol. 239 115–125. 10.1016/j.jbiotec.2016.10.010
    1. Kushner J. A., Lawrence H. P., Shoval I., Kiss T. L., Devins G. M., Lee L., et al. (2008). Development and validation of a Patient-Reported Oral Mucositis Symptom (PROMS) scale. J. Can. Dent. Assoc. 74 59.
    1. Kwon Y. (2016). Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. OncoTargets Ther. 9 2007–2016. 10.2147/OTT.S96899
    1. Lalla R. V., Bowen J., Barasch A., Elting L., Epstein J., Keefe D. M., et al. (2014). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120 1453–1461. 10.1002/cncr.28592
    1. Lalla R. V., Gordon G. B., Schubert M., Silverman S., Hutten M., Sonis S. T., et al. (2012). A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. Support. Care Cancer 20 1797–1804. 10.1007/s00520-011-1277-7
    1. Lee W. J., Lee J. L., Chang S. E., Lee M. W., Kang Y. K., Choi J. H., et al. (2009). Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br. J. Dermatol. 161 1045–1051. 10.1111/j.1365-2133.2009.09290.x
    1. Limaye S. A., Haddad R. I., Cilli F., Sonis S. T., Colevas A. D., Brennan M. T., et al. (2013). Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119 4268–4276. 10.1002/cncr.28365
    1. Logan R. M., Stringer A. M., Bowen J. M., Gibson R. J., Sonis S. T., Keefe D. M. K. (2008). Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol. Ther. 7 1139–1145. 10.4161/cbt.7.7.6207
    1. Mallick S., Benson R., Rath G. K. (2016). Radiation induced oral mucositis: a review of current literature on prevention and management. Eur. Arch. Otorhinolaryngol. 273 2285–2293. 10.1007/s00405-015-3694-6
    1. Mayo B. J., Stringer A. M., Bowen J. M., Bateman E. H., Keefe D. M. (2017). Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. Cancer Chemother. Pharmacol. 79 233–249. 10.1007/s00280-016-3165-9
    1. Mego M., Chovanec J., Vochyanova-Andrezalova I., Konkolovsky P., Mikulova M., Reckova M., et al. (2015). Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement. Ther. Med. 23 356–362. 10.1016/j.ctim.2015.03.008
    1. Meirovitz A., Kuten M., Billan S., Abdah-Bortnyak R., Sharon A., Peretz T., et al. (2010). Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer - a prospective pilot study. Radiat. Oncol. Lond. Engl. 5:16 10.1186/1748-717X-5-16
    1. Meulendijks D., Henricks L. M., Sonke G. S., Deenen M. J., Froehlich T. K., Amstutz U., et al. (2015). Clinical relevance of DPYD variants c.1679T > G, c.1236G > A/HapB3 and c.1601G > A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 16 1639–1650. 10.1016/S1470-2045(15)00286-7
    1. Moslehi A., Taghizadeh-Ghehi M., Gholami K., Hadjibabaie M., Jahangard-Rafsanjani Z., Sarayani A., et al. (2014). N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Bone Marrow Transplant. 49 818–823. 10.1038/bmt.2014.34
    1. Nonzee N. J., Dandade N. A., Patel U., Markossian T., Agulnik M., Argiris A., et al. (2008). Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis?: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 113 1446–1452. 10.1002/cncr.23714
    1. Ozben T. (2015). Antioxidant supplementation on cancer risk and concurrent use of antioxidants during cancer therapy: an update. Curr. Top. Med. Chem. 15 170–178. 10.2174/1568026615666141209160918
    1. Peterson D. E., Boers-Doets C. B., Bensadoun R. J., Herrstedt J. Esmo Guidelines Committee. (2015). Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann. Oncol. 26(Suppl. 5) v139–v151. 10.1093/annonc/mdv202
    1. Peterson D. E., Keefe D. M., Sonis S. T. (2012). New frontiers in mucositis. Am. Soc. Clin. Oncol. Educ. Book 2012 545–551. 10.14694/EdBook_AM.2012.32.545
    1. Pico J., Avila-Garavito A., Naccache P. (1998). Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3 446–451.
    1. Prisciandaro L. D., Geier M. S., Butler R. N., Cummins A. G., Howarth G. S. (2011). Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol. Ther. 11 671–677. 10.4161/cbt.11.7.14896
    1. Rao N. G., Trotti A., Kim J., Schell M. J., Zhao X., Amdur R. J., et al. (2014). Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 50 765–769. 10.1016/j.oraloncology.2014.06.001
    1. Ribeiro R. A., Wanderley C. W. S., Wong D. V. T., Mota J. M. S. C., Leite C. A. V. G., Souza M. H. L. P., et al. (2016). Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemother. Pharmacol. 78 881–893. 10.1007/s00280-016-3139-y
    1. Riley P., Glenny A.-M., Worthington H. V., Littlewood A., Clarkson J. E., McCabe M. G. (2015). Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst. Rev. 23:CD011552 10.1002/14651858.CD011552.pub2
    1. Riley P., McCabe M. G., Glenny A.-M. (2016). Oral cryotherapy for preventing oral mucositis in patients receiving cancer treatment. JAMA Oncol. 2 1365–1366. 10.1001/jamaoncol.2016.2680
    1. Rm L., Rj G., St S., Dm K. (2007). Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 43 395–401. 10.1016/j.oraloncology.2006.04.011
    1. Roldan C. J., Nouri K., Chai T., Huh B. (2017). Methylene blue for the treatment of intractable pain associated with oral mucositis. Pain Pract. 10.1111/papr.12566 [Epub ahead of print].
    1. Rubenstein E. B., Peterson D. E., Schubert M., Keefe D., McGuire D., Epstein J., et al. (2004). Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 2026–2046. 10.1002/cncr.20163
    1. Rubin J. S., Osada H., Finch P. W., Taylor W. G., Rudikoff S., Aaronson S. A. (1989). Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 86 802–806. 10.1073/pnas.86.3.802
    1. Rugo H. S., Pritchard K. I., Gnant M., Noguchi S., Piccart M., Hortobagyi G., et al. (2014). Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann. Oncol. 25 808–815. 10.1093/annonc/mdu009
    1. Rugo H. S., Seneviratne L., Beck J. T., Glaspy J. A., Peguero J. A., Pluard T. J., et al. (2016). Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): results of the SWISH trial. J. Clin. Oncol. 34:189 10.1200/jco.2016.34.26_suppl.189
    1. Sachak T., Arnold M. A., Naini B. V., Graham R. P., Shah S. S., Cruise M., et al. (2015). Neutropenic enterocolitis: new insights into a deadly entity. Am. J. Surg. Pathol. 39 1635–1642. 10.1097/PAS.0000000000000517
    1. Sanguineti G., Sormani M. P., Marur S., Gunn G. B., Rao N., Cianchetti M., et al. (2012). Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 83 235–242. 10.1016/j.ijrobp.2011.06.2000
    1. Schubert M. M., Eduardo F. P., Guthrie K. A., Franquin J.-C., Bensadoun R.-J. J., Migliorati C. A., et al. (2007). A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support. Care Cancer 15 1145–1154. 10.1007/s00520-007-0238-7
    1. Schwab M., Zanger U. M., Marx C., Schaeffeler E., Klein K., Dippon J., et al. (2008). Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26 2131–2138. 10.1200/JCO.2006.10.4182
    1. Shameem R., Lacouture M., Wu S. (2015). Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Invest. 33 70–77. 10.3109/07357907.2014.1001893
    1. Sheibani K. M., Mafi A. R., Moghaddam S., Taslimi F., Amiran A., Ameri A. (2015). Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac. J. Clin. Oncol. 11 22–27. 10.1111/ajco.12288
    1. Shi V. J., Levy L. L., Choi J. N. (2016). Cutaneous manifestations of nontargeted and targeted chemotherapies. Semin. Oncol. 43 419–425. 10.1053/j.seminoncol.2016.02.018
    1. Skof E., Rebersek M., Hlebanja Z., Ocvirk J. (2009). Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 9:120 10.1186/1471-2407-9-120
    1. Sonis S., Andreotta P. W., Lyng G. (2017). On the pathogenesis of mTOR-associated stomatitis (mIAS) - studies using an organotypic model of the oral mucosa. Oral Dis. 23 347–352. 10.1111/odi.12616
    1. Sonis S., Elting L., Keefe D., Nguyen H., Grunberg S., Randolph-Jackson P., et al. (2015). Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. Support. Care Cancer 23 433–439. 10.1007/s00520-014-2395-9
    1. Sonis S., Treister N., Chawla S., Demetri G., Haluska F. (2010). Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116 210–215. 10.1002/cncr.24696
    1. Sonis S. T. (1998). Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 34 39–43. 10.1016/S1368-8375(97)00053-5
    1. Sonis S. T. (2002). The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit. Rev. Oral Biol. Med. 13 380–389. 10.1177/154411130201300502
    1. Sonis S. T. (2004). The pathobiology of mucositis. Nat. Rev. Cancer 4 277–284. 10.1038/nrc1318
    1. Sonis S. T. (2007). Pathobiology of oral mucositis: novel insights and opportunities. J. Support Oncol. 9 (Suppl 4) 3–11.
    1. Sonis S. T. (2010). Regimen-related gastrointestinal toxicities in cancer patients. Curr. Opin. Support. Palliat. Care 4 26–30. 10.1097/SPC.0b013e328335fb76
    1. Sonis S. T. (2011). Oral Mucositis. Pocket Book for Cancer Supportive Care. London: Springer Healthcare.
    1. Sonis S. T. (2013). Oral mucositis in head and neck cancer: risk, biology, and management. Am. Soc. Clin. Oncol. Educ. Book 10.1200/EdBook_AM.2013.33.e236
    1. Sonis S. T., Eilers J. P., Epstein J. B., LeVeque F. G., Liggett W. H., Mulagha M. T., et al. (1999). Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 85 2103–2113. 10.1002/(sici)1097-0142(19990515)85:10<2103::aid-cncr2>;2-0
    1. Sonis S. T., Elting L. S., Keefe D., Peterson D. E., Schubert M., Hauer-Jensen M., et al. (2004). Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 1995–2025. 10.1002/cncr.20162
    1. Sonis S. T., Hashemi S., Epstein J. B., Nair R. G., Raber-Durlacher J. E. (2016). Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol. 54 7–14. 10.1016/j.oraloncology.2016.01.005
    1. Sonis S. T., Tracey C., Shklar G., Jenson J., Florine D. (1990). An animal model for mucositis induced by cancer chemotherapy. Oral Surg. Oral Med. Oral Pathol. 69 437–443. 10.1016/0030-4220(90)90376-4
    1. Sorensen J. B., Skovsgaard T., Bork E., Damstrup L., Ingeberg S. (2008). Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 112 1600–1606. 10.1002/cncr.23328
    1. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., et al. (2004). Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351 2590–2598. 10.1056/NEJMoa040125
    1. Squier C. A., Kremer M. J. (2001). Biology of oral mucosa and esophagus. JNCI Monogr. 2001 7–15. 10.1093/oxfordjournals.jncimonographs.a003443
    1. Stein A., Voigt W., Jordan K. (2010). Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther. Adv. Med. Oncol. 2 51–63. 10.1177/1758834009355164
    1. Stiff P. J., Emmanouilides C., Bensinger W. I., Gentile T., Blazar B., Shea T. C., et al. (2006a). Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J. Clin. Oncol. 24 5186–5193. 10.1200/JCO.2005.02.8340
    1. Stiff P. J., Erder H., Bensinger W. I., Emmanouilides C., Gentile T., Isitt J., et al. (2006b). Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 37 393–401. 10.1038/sj.bmt.1705250
    1. Stringer A. M., Al-Dasooqi N., Bowen J. M., Tan T. H., Radzuan M., Logan R. M., et al. (2013). Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support. Care Cancer 21 1843–1852. 10.1007/s00520-013-1741-7
    1. Stringer A. M., Logan R. M. (2015). The role of oral flora in the development of chemotherapy-induced oral mucositis. J. Oral Pathol. Med. 44 81–87. 10.1111/jop.12152
    1. Svanberg A., Öhrn K., Birgegård G. (2015). Caphosol(®) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. Eur. J. Oncol. Nurs. 19 50–53. 10.1016/j.ejon.2014.07.011
    1. Theis V. S., Sripadam R., Ramani V., Lal S. (2010). Chronic radiation enteritis. Clin. Oncol. 22 70–83. 10.1016/j.clon.2009.10.003
    1. Treister N., Nieder M., Baggott C., Olson E., Chen L., Dang H., et al. (2017). Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br. J. Cancer 116 21–27. 10.1038/bjc.2016.380
    1. Trotti A., Bellm L. A., Epstein J. B., Frame D., Fuchs H. J., Gwede C. K., et al. (2003). Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother. Oncol. 66 253–262. 10.1016/S0167-8140(02)00404-8
    1. Tsujimoto T., Yamamoto Y., Wasa M., Takenaka Y., Nakahara S., Takagi T., et al. (2015). L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol. Rep. 33 33–39. 10.3892/or.2014.3564
    1. United States Department of Health and Human Services (2010). Common Terminology Criteria for Adverse Events (CTCAE) - CTCAE_4.03. Available at: [accessed December 9, 2016].
    1. Uçüncü H., Ertekin M. V., Yörük O., Sezen O., Ozkan A., Erdoğan F., et al. (2006). Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced oral mucositis and myelosuppression: a controlled study in a rat model. J. Radiat. Res. 47 91–102. 10.1269/jrr.47.91
    1. Van Cutsem E., Köhne C.-H., Hitre E., Zaluski J., Chang Chien C.-R., Makhson A., et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360 1408–1417. 10.1056/NEJMoa0805019
    1. Van Cutsem E., Köhne C.-H., Láng I., Folprecht G., Nowacki M. P., Cascinu S., et al. (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29 2011–2019. 10.1200/JCO.2010.33.5091
    1. Van Sebille Y. Z. A., Stansborough R., Wardill H. R., Bateman E., Gibson R. J., Keefe D. M. (2015). Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Curr. Oncol. Rep. 17:50 10.1007/s11912-015-0474-9
    1. Vasconcelos R. M., Sanfilippo N., Paster B. J., Kerr A. R., Li Y., Ramalho L., et al. (2016). Host-microbiome cross-talk in oral mucositis. J. Dent. Res. 95 725–733. 10.1177/0022034516641890
    1. Venook A. P., Niedzwiecki D., Lenz H.-J., Innocenti F., Mahoney M. R., O’Neil B. H., et al. (2014). CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J. Clin. Oncol. 32 5s 10.1200/jco.2014.32.18_suppl.lba3
    1. Viet C. T., Corby P. M., Akinwande A., Schmidt B. L. (2014). Review of preclinical studies on treatment of mucositis and associated pain. J. Dent. Res. 93 868–875. 10.1177/0022034514540174
    1. Villa A., Sonis S. T. (2015). Mucositis: pathobiology and management. Curr. Opin. Oncol. 27 159–164. 10.1097/CCO.0000000000000180
    1. Villa A., Sonis S. T. (2016). Pharmacotherapy for the management of cancer regimen-related oral mucositis. Expert Opin. Pharmacother. 17 1801–1807. 10.1080/14656566.2016.1217993
    1. Wardill H. R., Bowen J. M., Al-Dasooqi N., Sultani M., Bateman E., Stansborough R., et al. (2014). Irinotecan disrupts tight junction proteins within the gut : implications for chemotherapy-induced gut toxicity. Cancer Biol. Ther. 15 236–244. 10.4161/cbt.27222
    1. Webb G. J., Brooke R., De Silva A. N. (2013). Chronic radiation enteritis and malnutrition. J. Dig. Dis. 14 350–357. 10.1111/1751-2980.12061
    1. Wong K. H., Kuciejewska A., Sharabiani M. T. A., Ng-Cheng-Hin B., Hoy S., Hurley T., et al. (2016). A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiother. Oncol. 122 207–211. 10.1016/j.radonc.2016.06.015
    1. Worthington H. V., Clarkson J. E., Bryan G., Furness S., Glenny A.-M., Littlewood A., et al. (2011). Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst. Rev. 4:CD000978 10.1002/14651858.CD000978.pub5
    1. Yamamoto H., Ishihara K., Takeda Y., Koizumi W., Ichikawa T. (2013). Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats. BioMed Res. Int. 2013:276186 10.1155/2013/276186
    1. Yuan A., Sonis S. (2014). Emerging therapies for the prevention and treatment of oral mucositis. Expert Opin. Emerg. Drugs 19 343–351. 10.1517/14728214.2014.946403
    1. Zecha J. A. E. M., Raber-Durlacher J. E., Nair R. G., Epstein J. B., Sonis S. T., Elad S., et al. (2016). Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support. Care Cancer 24 2781–2792. 10.1007/s00520-016-3152-z

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅